parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in mast cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 40	0.85
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 8554

STXBP6 in oligodendrocytes, braak+0.51 (p 0.165) → -0.10 (p 0.802)receipt 8562
STXBP6 in dopamine neurons, braak+0.08 (p 0.840) → +0.86 (p 0.003)receipt 8563

receipt 8563: STXBP6 in dopamine neurons, braak

power: full sample +0.47 (p 0.051, n 18), 95% CI -0.00 to +0.77. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.46 (p 0.052, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.41 (p 0.093, n 18). could be the mix.
skeptic: leave-one-out range +0.40 to +0.63, sign flips 0; without severely affected donors +0.47 (p 0.051, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for STXBP6 in dopamine neurons.

case closed: nothing better to follow up.

receipt 8562: STXBP6 in oligodendrocytes, braak

power: full sample +0.05 (p 0.847, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.02 (p 0.942, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.02 (p 0.942, n 18). could be the mix.
skeptic: leave-one-out range -0.09 to +0.20, sign flips 4; without severely affected donors +0.05 (p 0.847, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for STXBP6 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts